Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: The diabetes control and complications trial/epidemiology of diabetes interventions and complications study (DCCT/EDIC)

Circulation

Volumn 119, Issue 22, 2009, Pages 2886-2893

  Pop Busui, Rodica ^a,e   Low, Phillip A ^c   Waberski, Barbara H ^d   Martin, Catherine L ^a   Albers, James W ^b   Feldman, Eva L ^b   Sommer, Catherine ^c   Cleary, Patricia A ^d   Lachin, John M ^d   Herman, William H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Departments of Neurology   (United States)

^c MAYO CLINIC   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e 5570 D MSRB 2 ^*  (United States)

Author keywords

Autonomic nervous system; Diabetes mellitus, type 1; Diabetic neuropathies; Glucose

Indexed keywords

INSULIN;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; AUTONOMIC NEUROPATHY; BLOOD PRESSURE; BREATHING; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTENSIVE CARE UNIT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; RR INTERVAL; VALSALVA MANEUVER;

ADULT; AUTONOMIC NERVOUS SYSTEM; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HEART; HUMANS; INCIDENCE; INSULIN; MALE; MIDDLE AGED; PREVALENCE;

EID: 67649497933     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.837369     Document Type: Article

References (30)

1. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003;26:1895-1901.
2. Valensi P, Sachs RN, Harfouche B, Lormeau B, Paries J, Cosson E, Paycha F, Leutenegger M, Attali JR. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myo-cardial ischemia. Diabetes Care. 2001;24:339-343.
3. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553-1579.
4. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387-397.
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
6. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol. 1995;38:869-880.
7. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia. 1998;41:416-423.
8. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
9. DCCT/EDIC Writing Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159-2167.
10. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
11. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006;29:340-344.
12. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99-111.
13. Suarez GA, Opfer-Gehrking TL, Offord KP, Atkinson EJ, O'Brien PC, Low PA. The Autonomic Symptom Profile: a new instrument to assess autonomic symptoms. Neurology. 1999;52:523-528.
14. Low PA, Denq JC, Opfer-Gehrking TL, Dyck PJ, O'Brien PC, Slezak JM. Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. Muscle Nerve. 1997; 20:1561-1568.
15. Pfeifer MA, Cook D, Brodsky J, Tice D, Reenan A, Swedine S, Halter JB, Porte D Jr. Quantitative evaluation of cardiac parasympathetic activity in normal and diabetic man. Diabetes. 1982;31:339-345.
16. Gelber DA, Pfeifer M, Schumer M. Reliability and comparison of methods to calculate heart rate variability. Diabetes. 1995;44:30A. Abstract.
17. Gelber DA, Pfeifer M, Dawson B, Schumer M. Cardiovascular autonomic nervous system tests: determination of normative values and effect of confounding variables. J Auton Nerv Syst. 1997;62:40-44.
18. Pfeifer MA, Weinberg CR, Cook DL, Reenan A, Halter JB, Ensinck JW, Porte D Jr. Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care. 1984;7:447-453.
19. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev. 1994;10:339-383.
20. Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1996;46:873-880.
21. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy: the Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 1996;46:1470.
22. Stella P, Ellis D, Maser RE, Orchard TJ. Cardiovascular autonomic neuropathy (expiration and inspiration ratio) in type 1 diabetes: incidence and predictors. J Diabetes Complications. 2000;14:1-6.
23. Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005;48:164-171.
24. Ziegler D, Laux G, Dannehl K, Spuler M, Muhlen H, Mayer P, Gries FA. Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med. 1992;9:166-175.
25. Opfer-Gehrking TL, Low PA. Impaired respiratory sinus arrhythmia with paradoxically normal Valsalva ratio indicates combined cardiovagal and peripheral adrenergic failure. Clin Auton Res. 1993;3:169 -173.
26. Sandroni P, Ahlskog JE, Fealey RD, Low PA. Autonomic involvement in extrapyramidal and cerebellar disorders. Clin Auton Res. 1991;1:147-155.
27. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myo-cardial and endothelial dysfunction in diabetes. Diabetes. 2002;51: 514-521.
28. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med. 1980;49:95-108.
29. O'Brien IA, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med. 1991; 79:495-502.
30. Orchard TJ, CE LL, Maser RE, Kuller LH. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Res Clin Pract. 1996;34(suppl S):165-171.